11 studies found for:    pancreatic,cancer,PARP
Show Display Options
Rank Status Study
1 Recruiting Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Conditions: Germline BRCA1/2 Mutations and;   Metastatic Adenocarcinoma of the Pancreas
Interventions: Drug: Olaparib;   Drug: Placebo
2 Completed Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor);   Drug: Gemcitabine
3 Not yet recruiting Cediranib Maleate and Olaparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Conditions: Estrogen Receptor Negative;   HER2/Neu Negative;   Metastatic Pancreatic Adenocarcinoma;   Pancreatic Adenocarcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Stage III Pancreatic Cancer;   Stage IIIA Breast Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Small Cell Lung Carcinoma;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Small Cell Lung Carcinoma;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Small Cell Lung Carcinoma;   Stage IVA Pancreatic Cancer;   Stage IVB Pancreatic Cancer;   Triple-Negative Breast Carcinoma
Interventions: Other: 18F-Fluoromisonidazole;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Drug: Olaparib;   Procedure: Positron Emission Tomography
4 Completed Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage II Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: alvocidib;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Other: laboratory biomarker analysis
5 Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Pancreatic Adenocarcinoma;   Recurrent Pancreatic Carcinoma;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Veliparib
6 Active, not recruiting A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Conditions: Pancreatic Cancer;   Pancreatic Ductal Adenocarcinoma
Intervention: Drug: Rucaparib
7 Recruiting ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer
Condition: Metastatic Pancreatic Cancer
Intervention: Drug: ABT-888 and mFOLFOX-6
8 Active, not recruiting Veliparib in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Conditions: Adult Solid Neoplasm;   BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Estrogen Receptor Negative;   HER2/Neu Negative;   Hereditary Breast and Ovarian Cancer Syndrome;   Male Breast Carcinoma;   Progesterone Receptor Negative;   Recurrent Breast Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Prostate Carcinoma;   Triple-Negative Breast Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Veliparib
9 Active, not recruiting Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Conditions: Advanced or Recurrent Solid Tumors;   Breast Neoplasms;   Ovarian Cancer, Epithelial;   Ewing Sarcoma;   Small Cell Lung Carcinoma;   Prostate Cancer;   Pancreas Cancer
Intervention: Drug: BMN 673
10 Recruiting Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
Conditions: Advanced Ovarian Cancer;   Primary Peritoneal Cancer;   Advanced Breast Cancer;   Advanced Solid Tumors
Intervention: Drug: BMN 673
11 Active, not recruiting
Has Results
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats
Conditions: Ovarian;   Breast;   Prostate;   Pancreatic;   Advanced Tumours
Intervention: Drug: olaparib

Indicates status has not been verified in more than two years